Current understanding of von Willebrand's disease in women - Some answers, more questions

Haemophilia

Volumn 12, Issue SUPPL. 3, 2006, Pages 143-151

  Kouides, Peter A ^a,b  

^a Mary M Gooley Hemophilia Center   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Desmopressin; Menorrhagia; Postpartum haemorrhage; Screening; Von Willebrand's disease

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN; ESTROGEN; ETAMSYLATE; LEVONORGESTREL; MEFENAMIC ACID; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; TRANEXAMIC ACID;

AMENORRHEA; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOSIS; ENDOMETRIUM ABLATION; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; LABORATORY DIAGNOSIS; MEDLINE; MENORRHAGIA; MENSTRUATION DISORDER; MORBIDITY; MORTALITY; POSTOPERATIVE HEMORRHAGE; POSTPARTUM HEMORRHAGE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SURGICAL RISK; SYMPTOM; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTATICS; HUMANS; MASS SCREENING; MENORRHAGIA; POSTPARTUM HEMORRHAGE; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASES;

EID: 33646147384     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01272.x     Document Type: Review

References (71)

1. von Willebrand EA. Hereditar pseudohemofili. Fin Lakaresallsk Handl 1926; 67: 7-112.
2. Kouides PA. Females with von Willebrand disease - 72 years as the silent majority. Haemophilia 1998; 4: 665-76.
3. Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234-8.
4. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485-9.
5. Dilley A, Drews C, Miller C et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 630-6.
6. Woo YL, White B, Corbally R et al. von Willebrand's disease: An important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002; 13: 89-93.
7. Philipp CS, Dilley A, Miller CH et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost 2003; 1: 477-84.
8. Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia 1999; 5: 40-8.
9. Kouides PA, Burkhart P, Phatak P et al. Gynecological and obstetrical morbidity in women with type I von Willebrand disease: Results of a patient survey. Haemophilia 2000; 6: 643-8.
10. Rozeik C, Scharrer I. Gynecological disorders and psychological problems in 184 women with von Willebrand disease. Haemophilia 1998; 4: 293. (Abstract 547).
11. Barr RD, Sek J, Horsman J et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol 2003; 73: 108-14.
12. Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: A case-control study. Haemophilia 2003; 9: 292-7.
13. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrands disease or Factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314-21.
14. Ramsahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand's disease: A report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140-4.
15. Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia -experience with seven cases. Haemophilia 2004; 10: 477-82.
16. Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: A survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia 2004; 10: 158-61.
17. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002; 8: 787-93.
18. Leissinger C, Becton D, Cornell C, Gill JC. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001; 7: 258-66.
19. Kingman CEC, Kadir RA, Lee CA, Economides DL. 'The use of Levonorgestrel-releasing intrauterine system for the treatment of menorrhagia in women with inherited bleeding disorders'. Br J Obstet Gynaecol 2004; 111: 1425-8.
20. Caliezi C, Tsakiris DA, Behringer H, Kuhne T, Marbet GA. Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. Haemophilia 1998; 4: 845-9.
21. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. Willebrand disease in women with menorrhagia: A systematic review. BJOG 2004; 111: 734-40.
22. ACOG CommitteN on Gynecologic Practice: Committee Opinion: number 263, December 2001. von Willebrand's disease in gynecologic practice. Obstet Gynecol 2001; 98: 1185-6.
23. James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: A systematic review. Obstet Gynecol 2004; 104: 381-8.
24. Trasi S, Pathare AV, Shetty S, Ghosh K, Salvi V, Mohanty D. The spectrum of bleeding disorders in women with menorrhagia; a report from Western India. Ann Hematol 2005; 84: 339-42.
25. Kouides PA, Phatak P, Sham RL, Braggins L, Andrews C, Howard F. Long term clinical outcomes in women or without von Willebrand disease (VWD). HaemopIilia 2006; 12: (Suppl. 2): in press.
26. Claessens EA, Cowell CA. Acute adolescent menorrhagia. Am J Obstet Gynecol 1981; 139: 277-80.
27. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: A common cause of menorrhagia in adolescents. J Pediatr 2001; 138: 856-61.
28. Varadarajan R, Mikhail S, Kouides PA. The very high prevalence of disorders of hemostasis in adolescents with menorrhagia. Haemophilia 2006; I2: (Suppl. 2): in press.
29. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev 2000.
30. James AH. More than menorrhagia: A review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005; 11: 295-307.
31. Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990; 63: 36-8.
32. Winkler UH. Menstruation: Extravascular fibrinolytic activity and reduced fibrinolytic capacity. Ann N Y Acad Sci 1992; 667: 289-90.
33. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
34. Sadler JE. Willebrand disease type 1: A diagnosis in search of a disease. Blood 2003; 101: 2089-93.
35. Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women. N Engl J Med 1980; 302: 1093-4 (letter).
36. Alperin JB. Estrogens and surgery in women with von Willebrand's disease. Am J Med 1982; 73: 367-71.
37. Mangal AK, Naiman SC. Oral contraceptives and von Willebrand's disease. Can Med Assoc J 1983; 128: 1274 (letter).
38. Onundarson PT, Gumundsdottir BR, Arnfinnsdottir AV, Kjeld M, Olafsson O. Willebrand factor does not vary during the normal menstrual cycle. Thromb Haemost 2001; 85: 183-4 (letter).
39. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: Effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82: 1456-61.
40. Miller CH, Dilley A, Drews C, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002; 87: 1082-3 (letter).
41. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: Variability versus "variants". Blood 1980; 56: 712-6.
42. Blomback M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand's disease. Am J Hematol 1992; 40: 117-20.
43. Blomback M, Eneroth P, Landgren BM, Lagerstrom M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992; 67: 70-5.
44. He S, Bremme K, Silveira A, van RM, Blomback M. Hypercoagulation in surgical postmenopausal women having hormone replacement with overdose estradiol. Blood Coagul Fibrinolysis 2001; 12: 677-81.
45. Prasad RN, Koh SC, Viegas OA, Ratnam SS. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel. Clin Appl Thromb Hemost 1999; 5: 60-70.
46. Solerte SB, Fioravanti M, Spinillo A, Ferrari E, Guaschino S. Influence of triphasic oral contraceptives on blood rheology and hemostatic and metabolic patterns in young women. Results of a three-year study. J Reprod Med 1992; 37: 725-32.
47. Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-6.
48. Hall G, Blomback M, Landgren BM, Bremme K. Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women. Fertil Steril 2002; 78: 1172-7.
49. David JL, Gaspard UJ, Gillain D, Raskinet R, Lepot MR. Hemostasis profile in women taking low-dose oral contraceptives. Am J Obstet Gynecol 1990; 163: 420-3.
50. Kadir RA, Lukes AS, Kouides PA, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005; 84: 1352-9.
51. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692-6.
52. Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002; 13: 225-31.
53. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313: 579-82 (see comments).
54. Cooke I, Lethaby A, Farquhar C. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Syst Rev 2000.
55. Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: Results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 784-90.
56. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-9.
57. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: A systematic review. Br J Obstet Gynaecol 2001; 108: 74-86.
58. Mol BW, Bongers MY, Brolmann HA. Treatment of menorrhagia. Lancet 2001; 357: 1886-7.
59. Kouides PA, Phatak P, Sham RL, Braggins L, Andrews C, Howard F. The efficacy and safety of the levonorgestrel device (MIRENA TM) for bleeding disorder-related menorrhagia in an American cohort. Haemophilia 2006; I2: (Suppl. 2): in press.
60. Lukes AS, Perry S, Ortel TL. Willebrand's disease diagnosed after menorrhagia worsened from levonorgestrel intrauterine system. Obstet Gynecol 2005; 105: 1223-6.
61. Kujovich J. Willebrand disease and pregnancy. J Thromb Haemost 2005; 3: 246-53.
62. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 909-18.
63. Sanchez-Luceros A, Meschengieser SS, Marchese C et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14: 647-51.
64. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-82.
65. Deng L, Bremme K, Hansson LO, Blomback M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994; 84: 941-5.
66. Hanna W, McCarroll D, McDonald T et al. Variant von Willebrand's disease and pregnancy. Blood 1981; 58: 873-9.
67. Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 282-5.
68. Roque H, Funai E, Lockwood CJ. Willebrand disease and pregnancy. J Matern-Fetal Med 2000; 9: 257-66.
69. Federici AB, Castaman G, Mannucci PM. Italian Association of Hemophilia Centers (AICE): Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8: 607-21.
70. Biggs R, Matthews JM. The treatment of hemorrhage in von Willebrand's disease and the blood levels of factor VIII (AHG). Br J Haematol 1963; 9: 203.
71. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.